Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-cash Items (2018 - 2025)

Historic Non-cash Items for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $177.7 million.

  • Revolution Medicines' Non-cash Items rose 4710.26% to $177.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.7 million, marking a year-over-year increase of 4710.26%. This contributed to the annual value of $118.8 million for FY2024, which is 329.63% up from last year.
  • As of Q3 2025, Revolution Medicines' Non-cash Items stood at $177.7 million, which was up 4710.26% from $178.5 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Non-cash Items registered a high of $179.6 million during Q1 2025, and its lowest value of $44.4 million during Q3 2021.
  • For the 5-year period, Revolution Medicines' Non-cash Items averaged around $97.8 million, with its median value being $84.0 million (2021).
  • The largest annual percentage gain for Revolution Medicines' Non-cash Items in the last 5 years was 10855.86% (2021), contrasted with its biggest fall of 4914.65% (2021).
  • Over the past 5 years, Revolution Medicines' Non-cash Items (Quarter) stood at $84.0 million in 2021, then grew by 1.46% to $85.2 million in 2022, then surged by 35.02% to $115.0 million in 2023, then increased by 3.3% to $118.8 million in 2024, then surged by 49.58% to $177.7 million in 2025.
  • Its Non-cash Items stands at $177.7 million for Q3 2025, versus $178.5 million for Q2 2025 and $179.6 million for Q1 2025.